Monashee Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Monashee Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100,000	Closed	-$6.83M	–	596
2021 Q1	$6.83M	Buy	+100,000	New	+$8.09M	1.05%	8
2019 Q3	–	Sell	-100,000	Closed	-$4.38M	–	224
2019 Q2	$4.38M	Buy	+100,000	New	+$5.64M	1.13%	24
2017 Q3	–	Sell	-49,390	Closed	-$1.5M	–	64
2017 Q2	$1.24M	Buy	+49,390	New	+$1.14M	0.52%	52

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Monashee Investment Management's BHVN Position: Q2 2021 in Review

Monashee Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 100,000 shares — an estimated $6.83M sold.

Monashee Investment Management first reported a position in BHVN in Q2 2017 and held it in 3 quarters. The position peaked at $6.83M in Q1 2021. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Monashee Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Monashee Investment Management sold 100,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $6.83M.
Monashee Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 3 quarters.
Monashee Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.83M in Q1 2021.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Monashee Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.